vitamin D hormone in skin, the immune system, a possible role in the pancreas, i.e., in the islet cells, and a possible role in female reproduction. This review also raises the intriguing question of whether vitamin D plays an important role in embryonic development, since vitamin D deficiency does not prohibit development, nor does vitamin D receptor knockout. The final section reviews some interesting analogs of the vitamin D hormone and their possible uses. The review ends with possible ideas with regard to future directions of vitamin D drug design. stration of new biological actions of 1,25-(OH) 2 D 3 , in particu-I. METABOLIC ACTIVATION OF VITAMIN D lar, its effects on the regulation of growth and differentiation of certain specialized cell types (sect. IV), which represent A. Introduction involvements of vitamin D not even envisioned when 1,25-(OH) 2 D 3 was first discovered. Furthermore, the knowledge An appreciation that vitamin D 3 represents only a pre-of vitamin D metabolism also provided the impetus to study cursor to its functionally active form, 1a,25-dihydroxyvitamin the regulation of cytochrome P-450-containing enzymes in-D 3 [1,25-(OH) 2 D 3 ], is arguably one of the most important volved in the process as well as stimulating the chemical developments in vitamin research during the latter half of synthesis of a wide range of vitamin D analogs (sect. V). This the 20th century. The discovery of the two activation steps review seeks to summarize our current understanding of involved in the metabolism of vitamin D 3 to the hormone the molecular events surrounding the physiological action of 1,25-(OH) 2 D 3 (sect. I) set the stage for the elucidation of the vitamin D in these many varied areas. For a more detailed role of vitamin D in the physiological events involved in account of the subjects described in this review, particularly calcium and phosphate homeostasis (sect. II). The realization those of a clinical nature, the reader is directed to a recently that it was the metabolites of vitamin D that were important published text (96) . led to an intense focus on the molecular events surrounding the mechanism of action of 1,25-(OH) 2 let light (270-300 nm range). Alternatively, vitamin D, in D target tissues including enterocytes, osteoblasts, keratinocytes, and parathyroid cells. Thus it is now known that the form of either vitamin D 2 or vitamin D 3 , can be derived from dietary sources (Fig. 1A) . Both vitamin D 3 and vita-CYP24 will use 1,25-(OH) 2 D 3 as substrate also. Because CYP24 is widely distributed around the body, is strongly min D 2 undergo the same activation process, involving first 25-hydroxylation in the liver, followed by 1a-hydrox-induced in target cells by 1,25-(OH) 2 D 3 , and prefers 1,25-(OH) 2 D 3 as substrate to 25-OH-D 3 , its role appears to be ylation in the kidney, to make the biologically active compounds 1,25-(OH) 2 2 D 3 degradation, collectively known as the C-24 1B). There is little evidence that these two active forms differ in their mode of action, and because most is known oxidation pathway which starts with 24-hydroxylation and culminates in the formation of the biliary excretory form, about the synthesis and action of 1,25-(OH) 2 D 3 , this review focuses on the natural D 3 compound. The metabolic calcitroic acid (Fig. 3 ). Thus our current view is that both the synthesis and degradation of 1,25-(OH) 2 D 3 are tightly activations of vitamin D 3 are carried out by specific cytochrome P-450-containing enzymes, the vitamin D 3 -25-hy-regulated events, attesting to the fact that the concentration of this potent hormone requires fine control at the droxylase (CYP27) and possibly another P-450 in the hepatocyte and the 25-hydroxyvitamin D-1a-hydroxylase cellular level, and hence a set of highly specific and finely tuned cytochrome P-450 exist for the purpose. (CYP1a) in the renal proximal tubular cell. Both of the known hydroxylases are located in the inner mitochondrial membrane of these cells (Fig. 2) . The synthesis of C. Hepatic 25-Hydroxylation 25-hydroxyvitamin D 3 (25-OH-D 3 ) by the liver appears to be only loosely regulated, whereas the synthesis of 1,25-(OH) 2 D 3 by the renal 1a-hydroxylase is tightly regulated Vitamin D does not circulate for long in the bloodstream but, instead, is immediately taken up by adipose by the levels of plasma 1,25-(OH) 2 D 3 and calcium. The renal enzyme is strongly upregulated by the hormone tissue for storage or liver for further metabolism. In humans, tissue storage of vitamin D can last for months or parathyroid hormone (PTH), a point that is discussed further in section II. A third vitamin D-related mitochondrial even years. Ultimately, vitamin D 3 undergoes its first step of activation, namely, 25-hydroxylation, in the liver (28) cytochrome P-450-containing enzyme, the 25-hydroxyvitamin D-24-hydroxylase (CYP24), was originally believed (Fig. 1B) . Early data suggested that the liver is the only significant site of 25-hydroxylation in vivo, although there to be exclusively located in the kidney and to be involved only in the metabolism of 25-OH-D 3 to 24,25-dihydroxyvi-were occasional reports of intestinal and renal extracts containing this activity (346) . Research, therefore, fotamin D 3 [24,25-(OH) 2 D 3 ]. The 24-hydroxylation of 1,25-(OH) 2 D 3 was first realized with the isolation of 1,24,25-cused on purification of the major hepatic enzyme activity.
Over the years, there has been some controversy over (OH) 3 D 3 and subsequently shown to occur in all vitamin whether 25-hydroxylation is carried out by one enzyme (252) . 1 The primary amino acid sequences of three species of CYP27 are depicted in Figure 4 . Even though 25-hydroxor two and whether this cytochrome P-450-based enzyme ylation of a variety of vitamin D compounds, including is found in the mitochondrial or microsomal fractions of vitamin D 3 , has been clearly demonstrated in cells transliver. Madhok and DeLuca (207) reported that a rat liver fected with CYP27 (119), there is still some skepticism in microsomal system requiring NADPH, molecular oxygen, the vitamin D field that a single cytochrome P-450 can a flavoprotein, and a cytochrome P-450 was capable of explain all the metabolic findings observed over the past 25-hydroxylation of vitamin D 3 , but the cytochrome Ptwo decades of research. The many unexplained observa-450 responsible has never been cloned. There was some tions suggesting that other cytochrome P-450 might perspeculation that the microsomal enzyme might be form 25-hydroxylation of vitamin D at nanomolar concen-CYP2C11, but this cytochrome is male specific (129) and trations of substrate that exist in vivo include the followother data have also been presented that indicate that ing. 1) Perfused rat liver studies by Fukushima et al. (104) human microsomes do not possess 25-hydroxylase activdemonstrate kinetics consistent with two 25-hydroxylase ity (285) . Recently, Axen et al. (9) have purified a pig liver enzyme activities: a high-affinity, low-capacity form (premicrosomal 25-hydroxylase with an NH 2 -terminal sesumably microsomal) and a low-affinity, high-capacity quence different from that of CYP2C11 and that is capable form (presumably mitochondrial; CYP27). of the 25-hydroxylation of both vitamins D 2 and D 3 . Cur-2) Dietary studies show regulation, albeit weak, of the rently, only the mitochondrial 25-hydroxylase has been liver 25-hydroxylase in animals given normal intakes of vitapurified to homogeneity and subsequently cloned (7, 44, 351) . The cytochrome P-450 involved is known as CYP27 1 The term 27-hydroxylation has been suggested by a consortium or P-450c27 because it is a bifunctional cytochrome P-of cytochrome P-450 specialists to describe terminal hydroxylation of 450 which in addition to 25-hydroxylating vitamin D 3 also steroids given that methyl groups at C-26 and C-27 are indistinguishable.
The old nomenclature for this was 26-hydroxylation, and the literature carries out side-chain hydroxylation, including 27-hydroxcontains numerous references to 26-hydroxylation of vitamin D comylation of cholesterol-derived intermediates involved in pounds giving rise to 26-hydroxylated vitamin D metabolites, e.g., 25,26-(OH) 2 D 3 . bile acid biosynthesis (from which it derives its name) CYP1a and CYP24 are both renal cytochromes P-450 and 2-4 h after exposure to 1,25-(OH) 2 D 3 and is blocked by inhibitors of protein synthesis and transcription. In the appear to be reciprocally regulated, thereby implying CYP27 might have evolved to metabolize vitamin D after all. Thus, same model, the disappearance of the 1a-hydroxylase is mirrored by the reciprocal appearance of the renal 25-although CYP27 remains the best-characterized cytochrome P-450 capable of 25-hydroxylation, it may not be the only OH-D 3 -24-hydroxylase, in effect a complete ''switchover'' from 1a-to 24-hydroxylating activity in the isolated organ 25-hydroxylase, and its full physiological importance remains to be established.
over the 4-h period. The exact reciprocal regulation of the two enzymes, first demonstrated in vivo by Tanaka et al. The product of the 25-hydroxylation step, 25-OH-D 3 , is the major circulating form of vitamin D 3 and in humans (336) two decades ago, led some workers to postulate that the 1a-and 24-hydroxylases might share a single cytois present in plasma at concentrations in the range 10-40 ng/ml (25-125 nM) (140). The main reason for the stability chrome P-450 polypeptide chain, its catalytic properties modified by NH 2 -terminal truncation (111) or regulated of this metabolite is its strong affinity for the vitamin Dbinding (globulin) protein of blood (DBP) (70) . The meta-by the phosphorylation state of the ferredoxin component of the enzyme (300). The cloning of two distinct cytobolic fate of 25-OH-D 3 is dependent on the calcium requirements of the animal. An urgent need for calcium chromes P-450, representing 1a-hydroxylation and 24-hydroxylation, suggests the first hypothesis to be incorrect, results in renal 1a-hydroxylation, whereas an abundance of calcium results in 24-hydroxylation (see sect. II). These the switchover process probably being accomplished by de novo protein synthesis of the required cytochrome two alternative pathways are discussed in turn below.
P-450. The second hypothesis involving regulation of enzyme activity through ferredoxin phosphorylation re-D. Renal 1a-Hydroxylation mains a possibility for fine-tuning of enzyme activity, although the details of this remain obscure at this point. The cloning of CYP1a has already led to mapping of the The enzyme 25-hydroxyvitamin D 3 -1a-hydroxylase is responsible for the tightly regulated step that involves the human gene to chromosome 12q13.1-q13.3 (316), the same locus as the gene defect for vitamin D dependency rickets introduction of a 1a-hydroxyl group into the A ring of 25-OH-D 3 , thereby creating the hormone 1,25-(OH) 2 D 3 . The type I (192) , a disease cured by small doses of exogenous 1,25-(OH) 2 D 3 and which had been previously postulated specific location of this enzyme in the kidney became apparent (100) even before the unequivocal identification to be because of a mutated version of the 1a-hydroxylase (99) . The next decade will see a clarification of the molecof 1,25-(OH) 2 D 3 (139) . Experiments involving nephrectomized animals have confirmed that the kidney as the ma-ular and clinical aspects surrounding this key regulatory step of calcium homeostasis. jor source of the circulating pool of 1,25-(OH) 2 D 3 . The renal 1a-hydroxylase enzyme comprises a cytochrome PThere have been indications that there are extrarenal versions of the 1a-hydroxylase existing in cells of mono-450, a ferredoxin, and a ferredoxin reductase (112) (see Fig. 2 ). The cytochrome P-450 for the 1a-hydroxylase en-cyte/macrophage, placental, and keratinocyte lineages (4, 22, 83) . There is strong evidence that the extrarenal enzyme, CYP1a, was recently cloned from rat, mouse, and human (228a, 298, 316, 332) , and the amino acid sequences zyme located in macrophages plays a major role in certain granulomatous conditions (e.g., sarcoidosis), causing unof these are compared with the other known vitamin Drelated cytochromes P-450 in Figure 4 . Because of the controlled elevations of blood 1,25-(OH) 2 D 3 levels, which subsequently result in troublesome hypercalcemia and close resemblance with CYP27, it has been suggested that CYP1a (P-4501a) be termed CYP27B1 (298) . Both 1a-hy-hypercalciuria (3). The normal function of this and other extrarenal 1a-hydroxylases remains obscure at this time, droxylases have short mitochondrial targeting sequences but share many regions of similarity with other members although some have postulated a paracrine or autocrine role for locally produced 1,25-(OH) 2 D 3 . Once again, it is of the family including the classical heme-, ferredoxin-, and oxygen-binding sites indicated in Figure 4 . The 1a-safe to predict that the molecular basis for various reports of extrarenal activity in cultured cells in vitro (4, 22, 83) hydroxylase is induced by PTH through a cAMP/phosphatidylinositol 4,5-bisphosphate (PIP 2 )-mediated signal and in certain human disease states will be resolved shortly with the cloning of the renal enzyme (298, 316, transduction mechanism that is still to be defined at the molecular level (132) . The enzyme appears to be downreg-332), as will its mechanisms of regulation. ulated by vitamin D status, possibly through a VDR-mediated transcriptional mechanism involving the hormonal E. 24-Hydroxylation product 1,25-(OH) 2 D 3 , although there were early claims that 1,25-(OH) 2 D 3 might act directly on its own synthesis through an allosteric mechanism (117) . Work using the The discovery of 24,25-(OH) 2 D 3 (138, 327) predated even the identification of 1,25-(OH) 2 D 3 and the recognition perfused vitamin D-deficient rat kidney (281) elegantly shows that the downregulation of 1a-hydroxylation takes of 24-hydroxylation as a metabolic step allowed for the search for the enzyme activity. The relative ease with tion of CYP24 from undetectable to strongly detectable expression at the mRNA level within 4 h (297). This is which 24,25-(OH) 2 D 3 was generated in such large amounts was a clue that the metabolic step was upregulated rather consistent with the enzyme activity pattern first observed in the kidney but subsequently reported for a variety of than downregulated by vitamin D administration. The earliest report of the 25-OH-D 3 -24-hydroxylase was a subcel-vitamin D target cells after initial exposure to hormone (127, 202, 209) . Metabolic studies with the recombinant lular localization study (174) using vitamin D-replete chicken kidney tissue which established that the 24-hy-CYP24 protein produced in bacteria or insect cells have been equally enlightening. Akiyoshi-Shibata et al. (5) and droxylase is a mitochondrial cytochrome P-450-containing enzyme, and this was followed by a reconstitution experi-Beckman et al. (15) have shown that CYP24 is a multicatalytic enzyme capable of several if not all of the steps ment involving partially purified enzyme components (248). Evidence was also emerging both in vivo and in illustrated in Figure 3 . It is likely that CYP24 is able to catalyze three successive oxidations, two at C-24 and one vitro that the 24-hydroxylase was not confined to the kidney but could be found in classical vitamin D target tissues at C-23, to give an intermediate that is subsequently cleaved by an unknown mechanism. All prevailing eviincluding the intestine and bone (185, 347) . In the late 1970s, it became evident that 24-hydroxylation was proba-dence suggests that C-24 oxidation is a highly efficient process giving rise to molecules of lower biological activbly only the first step in an inactivation process. First, it was shown to be induced by 1,25-(OH) 2 D 3 itself (172, 187, ity (e.g., calcitroic acid) such that if C-24 hydroxylation is blocked by a general cytochrome P-450 inhibitor such 335, 337, 340) , and the product 1,24,25-(OH) 3 D 3 was 10 times less biologically active than 1,25-(OH) 2 D 3 (56, 335) . as ketoconazole, 1,25-(OH) 2 D 3 hormone action is extended (265) . This argues that the main role of the C-24 Second, 24,25-(OH) 2 D 3 and its 1a-hydroxylated analog, 1,24,25-(OH) 3 D 3 , could be converted to further metabolic oxidation pathway is attenuation of the biological signal inside target cells. products containing a 24-oxo and/or 23-hydroxy groups as well (237, 246, 330) . The perfused rat kidney was helpful in
Recently, this hypothesis was tested when St. Arnaud et al. (315) engineered a CYP24-null mouse. At this time, establishing the production of these catabolites (160) but revealed two further pieces to the puzzle of the metabolic the results have been reported only in abstract form, but it is clear that the defect is not lethal during embryonic role of 24-hydroxylation. First, the perfused rat kidney allowed for a clarification of the temporal relationship of development. Instead, at least one-half the mice exhibit hypercalcemia/hypercalciuria in early neonatal life and these catabolites, in effect, suggesting the existence of a pathway from 1,25-(OH) 2 D 3 and/or 25-OH-D 3 (160), and quickly die before weaning from nephrocalcinosis. The other half of animals survive and appear healthy perhaps second, the perfused kidney generated two side chaincleaved molecules: a 23-alcohol (159) and a 23-acid (208, due to the upregulation of some alternative vitamin Dcatabolic pathway (C-26 hydroxylation or 26,23-lactone 276), not observed previously in vitro. The 1a-hydroxylated 23-acid, calcitroic acid, is observed in vivo and has formation). All CYP24-null animals exhibit abnormal bone histology, characterized by excessive unmineralized bone been shown to be the principal biliary excretory form of 1,25-(OH) 2 D 3 (94) . These discoveries led to the rationaliza-matrix and reminiscent of that previously observed in experiments involving exogenous 1,25-(OH) 2 D 3 intoxication tion of many findings from a number of laboratories into a hypothesis that 24-hydroxylation is the first step of a (136). This could be caused by an inability of target cells, in this case osteoblasts, to turn off the 1,25-(OH) 2 D 3 signal target cell C-24 oxidation pathway (Fig. 3 ) whose major function is to convert 1,25-(OH) 2 D 3 to calcitroic acid (208, in the absence of the C-24 oxidation pathway. An alternative explanation that CYP24 is needed for the synthesis 276). The demonstration of vitamin D-inducible, calcitroic acid production in bone (UMR106) and kidney (208) was of some essential 24-hydroxylated metabolite of vitamin D [e.g., 24,25-(OH) 2 D 3 ] needed for a yet to be defined role followed by demonstration of vitamin D-inducible C-24 oxidation pathway activity in a number of vitamin D target in bone formation has been proposed (314) but seems unlikely for several reasons. Among the data that argue cells including intestine (Caco-2), keratinocyte (HPKIAras), and breast (T47D and MCF-7) (215, 278, 344) .
against such an essential role for 24-hydroxylated metabolites are the findings from the study of fluorinated analogs In the early 1990s, Okuda's group succeeded in cloning the cytochrome P-450, CYP24 or P-450cc24, represent-of vitamin D (149, 234, 338) . These analogs are irreversibly blocked in the C-24 and C-23 positions of the side chain ing the 24-hydroxylase (62, 148, 247) . The amino acid sequences of three species of CYP24 are shown in Figure with one or more atoms of fluorine and therefore unable to undergo 24-or 23-hydroxylation. However, they are 4. It belongs to the same subfamily as the other two known vitamin D-related cytochromes. The structure of the gene fully biologically active in all known in vivo functions of vitamin D. Furthermore, the biochemical machinery for CYP24 has been described for several species (rat, mouse, and human), and in each case shown to possess required for transducing the signal from a 24-hydroxylated metabolite has never been satisfactorily demonstrated in two VDRE in its proximal promoter (249, 367, 368). These VDRE allow for the 1,25-(OH) 2 D 3 VDR-mediated upregula-bone (or any other) cells. Thus it appears that 24-hydrox-ylation is not essential for vitamin D to fulfill its many is a very complex one (see Fig. 5 ) that involves many hormones, most of which are known but some that are biological roles in vertebrate biology. Therefore, evidence from the CYP24-null mouse seems to confirm our hypothe-not. From this discussion, it will become apparent that the vitamin D endocrine system is the basic one in managing sis that the C-24 oxidation pathway is a complex, selfinduced mechanism for limiting the action of 1,25-(OH) 2 D 3 calcium of plasma, with equally important roles for the parathyroid hormone and calcitonin. in vitamin D target cells once the initial wave of gene expression has been initiated (see sect. III). This is discussed in greater detail in section V.
B. Role of Parathyroid Gland and Its Hormone

II. ROLE OF VITAMIN D IN CALCIUM HOMEOSTASIS
For many years it has been clearly recognized that the parathyroid gland is the calcium-sensing organ in the body (266, 270, 283) . Thus, in response to even slight A. Development of Calcium hypocalcemia, the parathyroid glands react within secHomeostatic Mechanisms onds to secrete the 84-amino acid peptide hormone PTH (302) . This hormone then initiates the sequence of events that results in the mobilization of calcium to replace that Calcium is undoubtedly one of the most tightly regulated substances in plasma of higher animals (81, 270) . Its which has been taken from plasma.
There has been a great deal of recent effort expended concentration is held constantly at 1 mmol ionized calcium or 10 mg/100 ml of total calcium. The ionized calcium in the direction of the calcium receptor for the parathyroid glands. The calcium receptor is well known (39, 225) and concentration of plasma is very close to that found in seawater (270) , and it is believed that the evolution of appears to act in a cAMP-dependent mechanism to facilitate the secretion of PTH. This calcium receptor may play the calcium homeostatic system took place as animals emerged from the sea into fresh water and further onto an important role in other tissues as well. Interested readers are directed elsewhere (301) . The PTH has a lifetime land. Very likely the dependence of a number of life's essential functions on calcium occurred because of the in plasma that can be measured in minutes if not seconds (238) . The receptor for the PTH is known and has been constancy and abundance of calcium in seawater. Among them are the neural transmission, muscle contraction (and cloned (289). This receptor is found throughout the length of the nephron of kidney, is not found in the intestine, relaxation), exocrine secretion, blood clotting, and the adhesion of cells to each other. The presence of calcium and is found in the osteoblasts but not osteoclasts of the skeleton (2). In the kidney, the PTH plays an important in abundance in seawater also made understandable the use of calcium in the construction of structural elements role in many functions (101). Well known is that it blocks reabsorption of phosphate causing a phosphate diuresis such as the skeleton. As animals emerged into fresh water, resulting in a drop in ambient calcium concentration, it (39) . In the proximal convoluted tubule cells, it activates the 25-hydroxyvitamin D-1a-hydroxylase (25-OH-D 3 -1a-immediately brought into need the ability to mobilize calcium to meet the needs of the very critical functions such OHase) that converts 25-hydroxyvitamin D 3 to the active hormone, 1,25-(OH) 2 D 3 (109, 298, 340) . As already disas neural transmission and muscle contraction. This only intensified as animals emerged from fresh water onto land cussed in section I, the 25-OH-D-1a-OHase has now been cloned by three research groups (298, 316, 332) that will where calcium availability was even more limited than in fresh water. Furthermore, the gravitational forces applied undoubtedly result in our understanding of the molecular mechanism whereby PTH activates the 1a-OHase. At the to the terrestrial animals must have increased the need for a structurally sound skeleton. Thus the evolved mam-present time, it is known that PTH through cAMP (141) activates the 1a-OHase by increasing the mRNA encoding mal had many problems to solve before it could live as we now know life. It must be able to aggressively acquire for this important enzyme (298) . Whether it acts at the transcriptional level or elsewhere remains to be deterenvironmental calcium when required (81, 80, 130, 270, 283) . It had to have a constant source of calcium available mined. At the same time the PTH through cAMP activates the 1a-OHase, it markedly suppresses the 25-OH-D-24-to plasma to support nerve and muscle functions. It also had to be able to construct a skeleton of considerable OHase, the major enzyme involved in destruction of the vitamin D hormone as described in section I (297) . Again, strength to protect the organism and to provide for motility. Finally, the reproductive needs of the animals had to the mechanism of suppression of 24-hydroxylase (24-OHase) by PTH remains unknown, although there is be satisfied, including provision of calcium during embryonic and postembryonic development including construc-clearly a decrease in the mRNA encoding for the 24-OHase. These two actions result in a marked elevation of tion of an entirely new skeleton of the unborn animals. It is, therefore, clear that the calcium homeostatic system plasma levels of 1,25-(OH) 2 D 3 (341) . 
C. Physiological Actions
proceeds that is dependent on both the PTH and the vitamin D hormone (186, 362) . Again, these two hormones of 1a,25-Dihydroxyvitamin D 3 acting in concert cause the reabsorption of the last 1% of the filtered load of calcium into the plasma compartment. The consequences of an elevation of this major calThese sources of calcium then cause a rise in serum calcium mobilizing hormone are as follows: 1,25-(OH) 2 D 3 cium that then clears the sensing point of the calcium acts by itself to initiate active intestinal calcium transport receptor. This then shuts down the secretion of the PTH. in the small intestine (35) . This system has a relatively It does not appear that the PTH-related protein (PTHrP) long lifetime, being measured in days (123) , whereas the functions in this system but may play a role in abnormal other actions of 1,25-(OH) 2 329, 339) . The final result is that calcium is mobilized by the skeleton into the plasma compartment
The danger to hypercalcemia is calcification of soft tissues especially kidney, heart, aorta, and intestine, causby the action of the vitamin D hormone and the PTH. Of considerable importance is that vitamin D-deficient ani-ing organ failure and death. To guard against hypercalcemia, not only is the shut-off of the parathyroid gland immals having abundant calcium in their bones will not mobilize calcium from the skeleton in response to PTH unless portant but also the turning on of the C cells or the parafollicular cells of the thyroid to secrete the hormone vitamin D is provided (110, 271). Similarly, parathyroidectomized animals cannot mobilize calcium in response to calcitonin. This is a 34-amino acid peptide hormone that is responsible for lowering serum calcium by its action 1,25-(OH) 2 D 3 unless PTH is provided (110). Therefore, the presence of both the PTH and the vitamin D hormone are on the skeleton (57). It directly acts on osteoclasts and osteocytes reducing the calcium mobilizing activity and required for this system to operate in vivo. Whether this mechanism is through osteoclastic-mediated bone resorp-shutting down calcium coming from the skeleton (57).
Although other actions of calcitonin have been described tion or a membrane transport phenomenon remains to be determined. In the distal renal tubule, another mechanism in kidney and intestine, by far the most important in the regulation of serum calcium is that which occurs at the nal calcium absorption remains as one of the basic functions of 1,25-(OH) 2 D 3 . Quite independently of calcium is skeleton. There have been reports of calcitonin regulating vitamin D metabolism (16, 105) ; however, these largely the role of 1,25-(OH) 2 D 3 in stimulating intestinal absorption of phosphate (126, 180) . Both are active calcium are secondary to changes in parathyroid secretion, and there is no convincing evidence that calcitonin plays any transport mechanisms, but they appear to be independent of each other (63, 126, 180 3 stimulates the production of There has been considerable interest in other metab-calbindin D9k in mammals (342) and calbindin D28k in olites of vitamin D playing an important role in the regula-birds (68) to appear in the intestine. In the case of the tion of calcium mobilization in suppression of hypercalce-28k protein in birds, it is absent in deficiency and present mia, or in bone growth. Of particular importance are the in large amounts after stimulation by vitamin D (357) . A many studies carried out on 24,25-(OH) 2 D 3 . This com-vitamin D-responsive element has been demonstrated to pound has been alleged to be important in the regulation be present in the calbindin D9k promoter in mammals of calcium homeostasis (245) or in the formation of the (77) and the 28k mammalian gene (113) but that has not skeleton (33, 230, 255) or in counteracting the hypercalce-been shown for the calbindin D28k protein of birds. The mia activity of 1,25-(OH) 2 D 3 (201) . By now, extensive stud-exact molecular mechanism for initiating production of ies have been carried out with fluoro analogs, namely, the calbindin D28k remains to be determined. Further-24,24-F 2 -25-OH-D 3 to show that hydroxylation on the 24-more, if one studies the time course of appearance of the position has no functional significance (38, 149) . Thus 28k in birds as related to calcium absorption, there is no animals grown for two generations with 24,24-F 2 -25-OH-clear-cut correlation (125, 312) . The appearance of this D 3 as their sole source of vitamin D illustrate that 24-protein and calcium transport coincide as a function of hydroxylation is not required either for skeletal formation, time in response to vitamin D or 1,25-(OH) 2 D 3 . However, maintenance of calcemia, or growth of bone. More re-calcium absorption diminishes while calbindin D28k recently, a knockout of the 24-hydroxylase has been re-mains high in the gut. Therefore, there appears to be at ported, and the results are not at all clear as to whether least some discrepancy between calbindin D28k and cal-24-hydroxylation plays a role except in the destruction of cium transport. It has suggested that some other protein the potent hormone 1,25-(OH) 2 D 3 and its precursor, 25-or proteins are involved. This led to an analysis of a cal-OH-D 3 (313) . Further work using these models is required cium pump in the basolateral membrane that is induced before any conclusions can be reached.
by 1,25-(OH) 2 D 3 (357) . However, the degree of induction Other hormones such as estrogen and glucocorti-in the time course of its appearance is not certain to coids have significant effects on bone and calcium metab-account for the role of vitamin D in calcium transport. In olism, but they do not appear to be directly involved in short, the molecular mechanism of action of 1,25-(OH) 2 D 3 regulating serum calcium concentration. This seems in inducing intestinal calcium and phosphate transport is largely to be the role of the vitamin D hormone, the PTH, largely unknown. Wasserman and Feher (357) . factor that would inform the intestine of the skeletal needs for calcium. This basic observation was then shown to A vitamin D-deficient animal on a zero-calcium diet will provide an increase in serum calcium at the expense of be primarily the vitamin D endocrine system, and 1,25-(OH) 2 D 3 has been thought to be the agent that stimulates skeleton when given vitamin D. This mechanism requires the presence of PTH (110). Furthermore, 1,25-(OH) 2 D 3 is intestinal calcium absorption to meet the needs of the skeleton (34) . It is, therefore, abundantly clear that intesti-clearly a stimulator of osteoclastic bone resorption in cul-ture (269, 319) . However, the osteoclast has neither a re-cium homeostatic system was discovered. Figure 5 shows all of these mechanisms that work together in the regulaceptor to the PTH nor a receptor to the vitamin D hormone (223). Instead, a signal appears to arise from interaction tion of serum calcium concentration. of these two hormones with the osteoblast. This signal causes the osteoclast to resorb bone (221, 222, 328). There III. MOLECULAR MECHANISM OF ACTION is also the possibility that upon 1,25-(OH) 2 known about the activation process is shown in Figure 6 . the giant osteoclast. Further differentiation of the osteoclast precursor is catalyzed by the osteoclast differentiaIn the first place, activation of vitamin D target genes has been shown to require a specific nuclear receptor protion factor that is produced by the osteoblast in response to 1,25-(OH) 2 D 3 (328) .
tein, the VDR. Target genes are upregulated through binding of the VDR protein to specific DNA sequences termed reThe action of vitamin D in stimulating osteoclastic bone resorption may be to provide bone calcium for the sponse elements in the promoter regions of these genes. As shown at the top of Figure 6 , binding of 1,25-(OH) 2 D 3 to plasma but more likely to cause bone resorption in preparation for coupled formation to complete the bone-remod-the receptor increases heterodimerization of VDR with a cofactor, the retinoid X receptor (RXR), on a response eleeling process. This would argue that the vitamin D hormone is involved in this important function that strength-ment (169). Binding of the heterodimer to the response element induces a bend in the DNA of the promoter (151). ens bone and repairs microfractures that may have occurred during bone usage. At this stage, therefore, 1,25-Binding of 1,25-(OH) 2 D 3 to the receptor also appears to change the conformation at the COOH terminus of the VDR, (OH) 2 D 3 may be viewed as an important hormone that not only plays a role in bone calcium mobilization when permitting a region termed the AF-2 domain to interact with other transcription factors, including coactivator proteins required but also plays an important role in initiating bone remodeling and modeling systems required for shaping such as SRC-1 (216, 253, 279, 356). Recent exciting work indicates that coactivator proteins possess intrinsic histone bone and required for repairing bone (107, 319) .
acetylase activity (59, 345) . These coactivators bind to transcriptional ''integrators'' such as calcium-binding protein H. 1a,25-Dihydroxyvitamin D 3 Regulates the (CBP) and p300 (59, 152, 165) , which, in addition to other Parathyroid Gland functions, have also been shown to possess histone acetylase activity (179) . Thus recruitment of coactivators to a promoter by a liganded receptor appears to result in remod-A new addition to the calcium homeostatic system was the discovery that the parathyroid gland is a target eling of DNA structure through acetylation of histones and their subsequent release from DNA. This in turn leads to of vitamin D action. The initial work carried out by Stumpf et al. (324) showed that the parathyroid gland is a site opening of the promoter to the transcriptional machinery.
The net result of binding of liganded receptor to an upreguof localization of highly labeled 1,25-(OH) 2 D 3 . This was followed by two groups who demonstrated the presence lated target promoter is therefore to increase the rate of transcription of the gene, leading to increased production of VDR in that tissue (133, 145) . Finally, a 1,25-(OH) 2 D 3 suppression of parathyroid gland proliferation and of of the corresponding protein. It must be stressed at this point that a number of the details of this proposed mechanism are parathyroid production became known. A suppression of parathyroid secretion could be demonstrated in dialysis unclear at this point, including the exact sequence of events after receptor binding to the promoter, so the order of events patients treated with intravenous 1,25-(OH) 2 D 3 . The parathyroid gene was cloned (303) , and the VDRE was demon-presented in Figure 6 is somewhat speculative.
In contrast to genes that are upregulated by vitamin strated in the promoter region of the gene (85, 184) . This VDRE acts clearly in a mechanism to suppress transcrip-D, several genes, including PTH (85, 251) and interleukin (IL)-2 (6), have been shown to be downregulated by 1,25-tion of the parathyroid gene. Thus a new loop in the cal-(OH) 2 D 3 . The means by which this downregulation is carried out is not clear in all cases, and at least two possibilities exist. The first is that, as has been proposed for the IL-2 promoter, VDR may bind to a downregulatory response element and disrupt the binding of upregulatory transcription factors, leading to a decrease in transcription (6) . For other downregulated genes, the situation may be quite different, and binding of VDR to an inhibitory response element may lead to interactions with repressor proteins that decrease transcription of the gene. Interestingly, corepressor proteins such as nuclear receptor corepressor (NCoR) (142) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT) (60) have recently been found to bind, through intermediary proteins, to histone deacetylase enzymes (131, 233). Presumably in this situation the deacetylated histones then bind to the promoter of the downregulated gene and shut off transcription. The VDR has not yet been reported to bind to corepressor proteins, but given the rate at which such proteins are currently being discovered, it is possible that a corepressor that binds to VDR will be uncovered.
Phosphorylation of the receptor may also play a role in the induction of transcription by the VDR (73), perhaps through modulation of the affinity of VDR for the various cofactor proteins involved in transcription. Rapid phosphorylation of the VDR has been shown to occur in organ culture systems upon addition of ligand (41) . The phosphorylated residues have been localized to the ligandbinding domain of the protein. The exact functional consequences of this phosphorylation have been difficult to determine. Estrogen receptor phosphorylation by mitogenactivated protein kinase has been shown to have a direct and measurable effect on transcription (167), but this phosphorylation was mapped to the NH 2 -terminal AF-1 region of the estrogen receptor, which is lacking in VDR. Effects of phosphorylation on activation of the AF-2 domain, at the COOH terminus of the protein, have not yet been clearly shown for the VDR. Indeed, even the kinase (or kinases) responsible for the phosphorylation in vivo has yet to be determined. Some studies have suggested that serine-208 of the VDR can be phosphorylated by casein kinase II and that phosphorylation of this residue may cause increased transcriptional activity (162) . Other work has revealed that mutation of this serine failed to affect transcription, although alternate phosphorylation on adjacent serines was noted (135) . The exact effects of phosphorylation must await determination of the precise amino acids phosphorylated in vivo and the functional similarity to the subfamily that includes retinoic acid, thy-NMR and X-ray crystallography. The RXR structure showed that the DNA-binding domain, comprised of two zinc finger roid hormone, and peroxisome proliferator activator receptor (PPAR) receptors, to which it has sequence and motifs, consists of two a-helixes oriented at approximately right angles to one another (194) . One helix, termed the structural resemblance. The VDR has been cloned from several species (12, 42, 92, 164, 219) and shows consider-orientation helix, thought to be critical for recognition of the receptor response element was proposed to fit into the able similarity between species in size and sequence. In the rat, for example, the VDR protein consists of 423 major groove of the DNA and bind to a specific DNA sequence in the response element. These domains contain amino acids, with a molecular mass of Ç50 kDa, whereas in the human the protein has an additional 4 amino acids two zinc atoms tetrahedrally coordinated to eight conserved cysteine residues. Both the zinc atoms and the cysteine at the NH 2 terminus, for a total of 427.
Like the other nuclear receptors, the VDR can be residues are necessary to maintain the three-dimensional structure required for response element recognition and divided by function into several domains. An illustration of the different domains of the VDR is shown in Figure DNA binding. The amino acid sequence of the DNA-binding domain is similar between members of the receptor super-7. At the NH 2 terminus is a truncated A/B domain of Ç20 amino acids, to which little function has yet been ascribed family, suggesting that these structures can be used as a model for that of the VDR. for the VDR. After this, the DNA-binding domain, termed the C domain, is located between amino acids 20 and 90.
There is as yet no direct evidence for the structure of the VDR-RXR complex bound to DNA. However, the A D or hinge domain is located approximately between amino acids 90 and 130, followed by the COOH-terminal crystal structure of the TR and RXR DNA binding domains complexed to a DR4 response element has been deter-E or ligand-binding domain between amino acids 130 and 423. The ligand-binding domain of the protein is a complex mined (272) . With the use of this structure as a model, the VDR DNA-binding domain was hypothesized to have region of the protein, responsible for high-affinity binding of ligand, for dimerization with RXR, and for binding to specific amino acid contacts with RXR: between the asparagine residue 14 of VDR and RXR residues glutamine-49 transcription factors (95). It should be noted that exact delineation of the division between the hinge region and and arginine-52. In addition, lysine-68 and glutamate-69 of VDR were modeled to form salt bridges with RXR residues the ligand-binding domain is somewhat uncertain and is based on deletion analysis.
aspartate-39 and arginine-38, respectively. These interactions were thought to account for the optimal spacing of Knowledge of the structural and functional properties of the receptor proteins has increased dramatically three residues between the direct repeats of the vitamin D response element (DR3). in recent years, after the advent of systems which allow expression and purification of large quantities of receptor
The crystal structures of the ligand-binding domains of the RXR-a (without ligand) (32), the RAR-g (with ligand) protein from bacteria. This has allowed a piecemeal approach to determination of receptor domain structures; (279), and the TR-a 1 (with ligand) (356) have been determined. The ligand-binding domains of the RXR and RAR the DNA-binding and ligand-binding domains of several receptors have been expressed separately and purified, had been previously predicted to have a high content of ahelix (64, 204) , and this was confirmed by structural analysis. and structures have been determined by NMR or X-ray crystallography (32, 272) . In contrast, to this point, infor-All three ligand-binding domains were found to share a common secondary structure of 12 a-helixes, with a small conmation concerning the VDR has come primarily from sitedirected mutagenesis, in which the receptor cDNA is mu-tent of b-sheet. A comparison of the structures of the RAR and TR with that of the VDR is shown in Figure 8 . The tated and the mutant protein studied by transfection into mammalian cells (236) . No structural data are yet avail-COOH-terminal portion of the proteins, termed the AF-2 domain, has been determined to be critical for transcription. able concerning the VDR, but the other receptor domains may serve as models on which to base hypotheses about Removal of this portion of the protein results in decreased ligand-binding affinity and loss of transcriptional activation. the VDR and its properties.
Structures for the DNA-binding domains of other re-The structural data indicate that the helixes 11 and 12 of the RAR and TR may undergo a large conformational change ceptors, including the RXR, have been obtained using both in response to ligand binding, folding up around the ligand receptor that contact the ligand remain unknown, although some work has been done recently on affinity lain what the authors of the RAR paper term a mouse trap action to form a hydrophobic pocket (279). This brings the beling of the binding site (273) . Previous work with transfected cells has shown that deletion of the NH 2 -terminal amino acid residues on helix 12 which make up the AF-2 domain into position to interact with other transcription 116 amino acids of the VDR left a protein with measurable ligand binding activity, whereas deletion of the NH 2 -termifactors. The VDR shows sequence similarity to the RAR and TR in this region and may be expected to possess a similar nal 160 amino acids did not (220). More recent work with fusion proteins has shown that deletion of the NH 2 -termithree-dimensional structure and to undergo a similar conformational change upon ligand binding. nal 124 amino acids gave rise to a functional ligand-binding protein, whereas deletion to amino acid 172 did not The wild-type VDR binds its ligand, 1,25-(OH) 2 D 3 , with extremely high affinity, in the range of 10 010 M (208, (242) . From the other end, removal of the COOH-terminal 20 amino acids of the VDR resulted in a 10-fold loss of 282). Both the 1a-and 25-hydroxyl groups are critical for high-affinity binding, and the absence of either results in affinity for ligand, whereas removal of more than this number resulted in complete loss of ligand binding (236) . approximately a 500-fold decrease in affinity of ligand for the receptor (82) . The exact amino acid residues in the Thus a core domain of Ç300 amino acids was shown to be required for the protein to bind ligand with wild-type rapid nongenomic effects of vitamin D on calcium transport, termed transcaltachia (241). The physiological imaffinity. This is in accordance with the ligand-binding domains of the related receptors that have been crystallized, portance of these data is unclear. Whether these effects are mediated by the VDR or a different protein is also which were all expressed in bacteria as proteins of between 250 and 300 amino acids.
unclear. The development recently of a mouse model in which the VDR has been ablated (365) may provide some An alignment of the VDR ligand-binding domain sequence with that of the RAR and TR supports the possibility insight into the relevance of these reports, and into whether the VDR plays any role in them. that amino acids in the VDR directly in contact with ligand begin at approximately amino acid 220. In Figure 8 , amino
Recently, the promoters of the mouse (150) and human (226) VDR have been isolated. Some studies have acids in contact with ligand in the RAR and TR crystal structures are shaded. Inspection of this figure shows that the suggested that the VDR is upregulated by treatment with agents such as forskolin, which induce protein kinase A contact amino acids begin at helix 3 in both the RAR and TR. Based on sequence alignment, the same region of the (183) . Further study of these promoters will shed more light on the means by which VDR protein levels are regu-VDR begins at approximately amino acid 220, with a leucine residue that is conserved in all three proteins. Interestingly, lated inside target cells. work in which 10 amino acid segments of the VDR were sequentially deleted found that impairment of ligand binding C. Retinoid X Receptors and Other Coactivators did not occur until approximately amino acid 230, which is in accordance with this possibility (154) .
Site-directed mutagenesis of the VDR ligand-binding In the absence of cofactor proteins, the VDR is unable, at physiological concentrations of protein, to bind to most domain has been performed recently on several of the cysteine residues in the human protein (235) . Alteration response elements that have been described. This has become clear from both in vitro gel retardation assay experiof cysteine-288 to glycine resulted in severe attenuation of ligand binding at room temperature, whereas the same ments and from experiments involving receptor expression in yeast (155, 231, 310) . Work with the VDR and with related mutation at cysteine-337 resulted in a smaller decrease in affinity. The exact significance of this result is uncertain, receptors indicated that the RXR is the required cofactor.
The RXR was isolated several years ago, and initially although a contact between cysteine-237 and carbon-13 of retinoic acid was noted in the binding of retinoic acid its ligand and functional importance were unknown (211).
Subsequent work identified 9-cis-retinoic acid as a ligand to the RAR-g (279). Interestingly, in Figure 8 , the corresponding cysteine residue (cysteine-284) of the rat recep-for RXR (134) . It also became clear that RXR plays a critical role in binding to DNA of several different receptors, includtor aligns exactly with ligand-contacting amino acids in the RAR and TR, suggesting that this cysteine may in fact ing the VDR, the TR, the RAR, and the PPAR, among others (98, 173). In the absence of RXR, it appears that none of directly contact the ligand.
The VDR is generally expressed at relatively low levels these receptors binds efficiently to their response elements. Like other receptors, the RXR can be divided into functional in vivo. Target tissues, such as bone, kidney, and especially intestine, may have relatively high levels of receptor (3,000-domains, including an NH 2 -terminal A/B domain, a C domain which binds to DNA, and a COOH-terminal DE domain that 6,000 fmol/mg protein), but in other tissues, the levels are generally much lower (72) . The receptor has been shown binds ligand and activates transcription (58, 210). Heterodimerization with other receptors appears to be mediated to be present in most tissues that have been examined, including activated immune cells such as T cells, where it through two interfaces: one in the DNA-binding C domain (366) and another in the ligand-binding E domain (359). may play a role in modulating the levels of cytokines such as IL-2 (6). In contrast to other receptors, such as the gluco-Interestingly, in structural studies, the RXR ligand-binding E domain was found to crystallize as a dimer, and the dimer corticoid receptor, which is associated with a number of proteins, including heat shock proteins, in the cytoplasm interface occurred along helices 9 and 10, exactly where mutagenesis studies suggest RXR heterodimerizes with before hormone binding (146) , studies with radiolabeled 1,25-(OH) 2 D 3 have shown that the VDR is predominantly other receptors (32, 261) . This region of RXR from amino acids 389 to 429, termed the I box, is sufficient for strong nuclear (325) . Little information is available concerning whether any proteins associated with the VDR before DNA interaction between RXR and TR, but the same sequence provides only weak interaction with VDR. Additional NH 2 -binding. There are some data suggesting that many hormone-binding receptors, including VDR, contain a binding terminal RXR sequence is required for strong interactions with VDR (261), indicating a potential distinction between site for calreticulin in the DNA-binding domain (43 1 (216, 355) . Other coactivator proteins that have been one half-site was preferred by RXR, and if so, whether this preference was for the upstream or downstream site. discovered recently, including ACTR (59) and p/CIP (345) , join the rapidly enlarging group of such proteins. The For VDR, as for the other receptors that heterodimerize with RXR, it appears that RXR binds to the 5-half-site coactivators seem to fall into a family with many features in common, including size (Ç1,400 amino acids), structure and VDR the 3-half-site (189, 366), although there may be some exceptions to this rule. The polarity of this bind-(NH 2 -terminal Per-Arnt-Sim/basic helix-loop-helix domains, central receptor interaction domains) and activity ing has been shown to be important for maximal gene activation, with significantly lowered transcription rates (COOH-terminal histone acetylase domains). It seems likely that most, if not all, of the coactivator proteins will occurring if the response element orientation is reversed relative to the promoter start site. Binding of the VDR-be found to interact with VDR and activate transcription.
For example, both SRC-1 and TIF-1 have been shown RXR heterodimer to a response element is greatly increased by 1,25-(OH) 2 D 3 when salt concentrations are in to bind to the VDR (216, 355), whereas nuclear receptor coactivator protein (ACTR) has been shown to enhance the physiological range, i.e., 100-150 mM (169). Interestingly, for many of the receptors that heterodimerize with transcription from a vitamin D target gene in transfected cells (59) . However, it is not yet clear whether all coactiva-RXR, the natural ligand of RXR, 9-cis-retinoic acid, may not enhance DNA binding. Some findings indicate that tors interact with VDR equally well; some may function more effectively than others in the vitamin D system. An RXR may be unable to bind ligand while in a complex with another receptor (98). In addition, some in vitro reports additional possibility is that tissue-specific expression may be a significant factor in determining which coactivaindicate that the VDR-RXR complex is disrupted by addition of 9-cis-retinoic acid (205) . This contrasts with work tor works with the VDR. For example, the coactivator ACTR was shown to be expressed at relatively low levels in transfected cells indicating that both 1a,25-(OH) 2 D 3 and 9-cis-retinoic acid enhanced reporter gene expression in kidney, an important vitamin D target tissue (59) . This may indicate that other coactivators play a more imfrom a vitamin D-responsive promoter (291). The reason for these conflicting results is unclear; it may be an experi-portant role in transcriptional activation of vitamin D- controlled genes, at least in this tissue. mental artifact, or it may be that the additional proteins that interact with the VDR-RXR heterocomplex in vivo, Whether VDR interacts with corepressor proteins to bring about downregulation of target genes is currently such as the coactivator/corepressor proteins, affect the conformation of the RXR and permit ligand to bind.
unclear. Like the coactivator proteins, the corepressor proteins appear to have many features in common. The The VDR has been shown to interact directly with a growing number of other transcription factors, including corepressors SMRT and NCoR (142), for example, have considerable sequence similarity, although NCoR postranscription factor IIB (TFIIB). The interaction of VDR with TFIIB has been characterized in several reports (27, 206) . sesses a large NH 2 -terminal region lacking in SMRT. In addition, both proteins appear to repress transcription TFIIB is a 30-kDa protein that was originally isolated as a cofactor associated with TATA-binding protein (120) . A re-through interactions with the Sin3 proteins, which bind to histone deacetylase enzymes (131, 233). However, unlike gion of VDR of Ç70 amino acids in the D domain has been reported to bind to a 43-residue NH 2 -terminal region of related receptors such as retinoic acid and TR, it is unclear whether the VDR is bound by corepressor proteins. At TFIIB (27, 203) . The sequence of TFIIB in this region is similar to that of a zinc finger, suggesting that the zinc finger least one corepressor protein, NCoR, has been reported not to bind to VDR at all. NCoR binds to a conserved motif may function in protein-protein interactions as well as DNA binding. Interestingly, one report suggests that bind-region of the TR and RAR, termed the CoR box, to exert its effects; binding of ligand to the TR or RAR causes ing of ligand to VDR causes dissociation of TFIIB from the receptor, which may indicate a complex interaction between dissociation of NCoR from receptor. NCoR does not bind to the CoR box region of the VDR, despite the similarity proteins before the initiation of transcription (217).
Interactions between the VDR and other factors are of the VDR sequence in this region to that of TR and RAR (142). This may explain why the VDR does not seem to less well characterized, although this work is progressing, particularly with regard to the coactivator proteins. Recent exhibit dominant negative silencing seen with both the TR and RAR (262, 286) . The possibility remains that other work indicates that VDR binds to SUG1/TRIP1, a nuclear protein that also binds to other receptors (355). It should corepressor proteins will be found to bind to the VDR and that this interaction is responsible for silencing at least be noted that the function of SUG1 in VDR-mediated transcription is unclear. SUG1 binds to the AF-2 domain of the some of the genes that are downregulated by vitamin D. VDR (216, 355), but because SUG1 has been found to be a D. Vitamin D Responsive Elements component of the proteasome complex in the nucleus, it may function primarily in receptor degradation.
As mentioned in section IIIA, responsive elements are the sequences of DNA, isolated from the promoters of vitaThe VDR has also been shown to bind to a growing (197) . Thus the results of such in vitro experiments must be interpreted with caution and, if possible, in vivo. of the first such response elements isolated was that of the rat osteocalcin gene (84) . Work with this and other vitamin For example, the report of VDR heterodimerization with TR and RAR may potentially be evaluated through the use D response elements, and with the response elements of other receptors, led to the demonstration that many re-transgenic animals in which RXR has been ablated, to determine whether VDR-responsive genes can still be exsponse elements consisted of two repeats of the half-site sequence AGGTCA separated by several nonspecified bases pressed. Unfortunately, ablation of RXR-a, the preferred partner for VDR, is a lethal mutation (90), but it is possible (75, 173, 349) . The variable that determines receptor specificity seems to be the number of nucleotides separating the that inducible knockouts of the RXR-a will provide insight into whether these other receptors can heterodimerize half-sites. The RXR has been shown to have a preference for two half-sites separated by a single nucleotide, termed with VDR and rescue the expression of VDR target genes. a DR-1 response element, whereas the VDR binds to a DR-3 element, the TR to a DR-4 element, and the RAR to a DR-E. Vitamin D-Dependent Genes, Their Roles, and 5 element (349) . Interestingly, almost all of the naturally Gene Complexity occurring VDRE isolated from genes upregulated by the VDR have fallen into the DR-3 category. The negatively regulated genes, such as those for PTH and IL-2, may not Many different genes have been shown to be responsive to vitamin D. Most of these genes play a direct role follow this rule. Initial work with the PTH gene indicated that the response element in this case consisted of only a in calcium endocrinology or bone formation and were the earliest examples of vitamin D response elements isosingle half-site. However, more recent work indicates that the PTH VDRE may in fact consist of two half-sites (76), lated. Examples of these include osteocalcin (84), osteopontin (243), PTH (251), the hydroxylases CYP24 (368) which may leave only a few exceptions, such as the IL-2 gene, to this rule (6) .
and CYP1a (298, 316, 332) , and the calbindin genes (69) . Many of these have been reviewed recently (75) . The roles One interesting aspect of the interaction between receptor and response element is the bend in the response of many of these genes in calcium endocrinology have become more evident in recent years. For example, the element DNA that is induced by binding of the VDR-RXR heterodimer (151) . This has been reported for binding bone protein osteocalcin is secreted by osteoblasts and represents the single greatest protein constituent of bone of related receptors, such as the RAR, to their response elements (71) . The degree of bending induced by the pro-by mass. Expression of this protein is upregulated by vitamin D, and it may play a significant role in maintaining tein complex is reportedly on the order of 30Њ. Although this bend is much lower in magnitude than that reported bone integrity (73) . On the other hand, several genes have been shown to be downregulated by vitamin D, including for binding of the TATA-binding protein to DNA (240), it is still appreciable. It is interesting to speculate on the the gene for PTH, which plays a critical role in controlling the levels of 1,25-(OH) 2 D 3 in serum. possible role of this induced bending, particularly in light of the finding that coactivator proteins and their cofactors Several of the hydroxylase enzymes that act directly on 1,25-(OH) 2 D 3 formation and degradation have been acetylate histones. It may be that the combination of DNA bending and histone dissociation acts to make the pro-shown to be controlled at the transcriptional level by 1,25-(OH) 2 D 3 . In particular, the hydroxylase enzyme CYP24 is moter of the target gene more accessible to transcription factors before transcriptional activation.
one of the most highly regulated genes that responds to vitamin D. This enzyme represents the major means by Some recent reports have suggested that a greater degree of flexibility exists for binding of VDR to response which 1,25-(OH) 2 D 3 is catabolized in vivo, and its importance is emphasized by recent gene knockout experiments elements. Work in vitro has suggested that VDR can bind to DR-3 response elements, such as the osteopontin in which loss of the enzyme was found to be lethal to at least 50% of the recipient mice (313) . The CYP24 gene is VDRE, as homodimers (291). Other work suggests that TR and RAR can act as heterodimeric partners with VDR highly upregulated by 1,25-(OH) 2 D 3 and contains two sets of VDRE in its promoter (61, 168, 368) . Both sets of eleon a response element, instead of RXR (292). In addition, response elements that do not fall into the DR-3 category ments are required for the gene to display maximum inducibility by vitamin D (168, 368). It therefore appears have been suggested to bind VDR, including DR-6 elements (264) and one element composed of an inverted that the presence of multiple copies of response elements are one way in which vitamin D target genes can be effirepeat of two half-site elements separated by nine bases (292). At present, the significance of this work is unclear. ciently upregulated.
In contrast to the preceding example, the hydroxyFor instance, it has been reported that although VDR can bind to the osteopontin response element as a homodi-lase enzyme CYP1a, which is responsible for catalyzing the formation of 1,25-(OH) 2 D 3 , is highly downregulated mer, the homodimer is transcriptionally inactive and the VDR-RXR heterodimer is required for transcriptional ac-by its product. This enzyme, expressed in the proximal The first insight into possible new functions of 1,25-Another set of genes that have been shown to be (OH) 2 D 3 beyond its actions in the regulation of calcium regulated by vitamin D are the calbindins. In mammals, and phosphorus as described in section II came as a result the calbindin D 9 K is expressed primarily in intestine, of studies involving the cellular and subcellular localizawhereas the calbindin D 28 K is expressed in kidney and tion of radiolabeled 1,25-(OH) 2 D 3 at high specific activity. other tissues. The calbindin D 9 K may play a role in absorp-This allowed the administration of physiological doses of tion of calcium from the gut, whereas the calbindin D 28 K 1,25-(OH) 2 D 3 and its detection by frozen section autoradimay be involved in reabsorption of calcium from glomeru-ography in target tissues (324, 325) . The result of this lar filtrate, although this has not been definitively shown. study in the late 1970s illustrated that not only was radioThe promoters of both of these genes have been cloned labeled 1,25-(OH) 2 D 3 localized in the nuclei of the entero-(74, 153, 331), and both have been reported to contain cyte of the small intestine, the distal renal tubule of the VDRE. Recent work on targeted gene disruption of the kidney, and the osteoblasts of bone, but were found in D 28 K has recently been reported in the mouse (311). This tissues not previously considered targets of vitamin D is not a lethal mutation, and the effects of this knockout action. These localizations were found specific inasmuch on regulation of calcium levels will be of great interest in as the localizations could be prevented by the administradeciphering the role of this protein in calcium transport. tion of unlabeled 1,25-(OH) 2 D 3 but not 25-OH-D 3 . Of great More recent and somewhat more surprising discoveries interest was the finding of 3 H-labeled 1,25-(OH) 2 D 3 in the of genes that are regulated by vitamin D include the discov-nuclei of the islet cells of the pancreas, keratinocytes of ery of VDRE in the promoters for a number of genes not skin, ovarian tissue, mammary epithelium, epithelial cells traditionally considered vitamin D targets. These include of the epididymis, certain neuronal tissue, promyelocytes, potential response elements in the promoters of several macrophages, and T lymphocytes. This unexpected develgenes, including integrin b 3 (52), fibronectin (264), atrial opment focused on the possibility that 1,25-(OH) 2 D 3 may natriuretic factor (163, 198) , c-fos (48, 290), PTHrP (182), carry out functions not previously appreciated and in tisand p21 (199) . The significance of the vitamin D regulation sues not previously considered targets of vitamin D acof many of these genes is unclear and may prove an interest-tion. This result was followed by the demonstration of ing area of study. In this regard, the recently developed the VDR in the parathyroid gland (133, 145) , in skin (305), mouse strain in which the receptor has been ablated may in the thymus (267) , and in ovarian cells (88) . Following provide an interesting vehicle for assessing the contribution this lead came the demonstration that the vitamin D horof the VDR to regulation of these genes (365).
mone carries out functions in many of these tissues, and still other functions remain to be discovered.
F. Target Cell Metabolic Enzymes
The metabolism of vitamin D by target cells has been B. Role of Vitamin D Hormone in the Parathyroid Gland shown to occur in a number of tissues, including kidney, intestine, and bone. In kidney and intestine in particular, upregulation of the 24-hydroxylase enzyme in response to Perhaps the most well-established new function of 1,25-(OH) 2 D 3 is in the parathyroid gland. Specific localiza-1,25-(OH) 2 D 3 treatment is rapid, occurring within 4 h, as shown by both Northern and enzymatic analyses (297) . Cul-tion of 1,25-(OH) 2 D 3 in the parathyroid gland (325) and the presence of VDR was provided by two independent tured bone cells have also been shown to possess highly inducible 24-hydroxylase activity (202) . These cells have laboratories (133, 145) . However, there had been considerable controversy as to whether the 1,25-(OH) 2 D 3 could been used to isolate catabolic products of 1,25-(OH) 2 D 3 that can be placed in a logical order on a degradative pathway suppress secretion or production of the PTH (114, 115, 302) . Early work failed to provide support for the idea leading from the active compound to inactive excretion products (82) . Thus it appears that the target cells for vita-that 1,25-(OH) 2 D 3 could, in fact, suppress parathyroid secretion in isolated parathyroid glands. Furthermore, 25-min D contain the means to regulate its activity at the cellular level. The additional level of control that this target cell OH-D 3 was continuing to be used as a suppressant of secondary hyperparathyroidism in renal failure patients metabolism provides over local concentrations of 1,25-(OH) 2 D 3 may be an important means by which tissues regu-on dialysis (274) . Notably, however, large amounts of this compound were needed to provide any degree of suppreslate the responsiveness of genes to vitamin D.
sion, usually of the order of 20 mg/day. Suppression of hyperproliferation of the keratinocyte and failure to differentiate is not found in vitamin D-deficient animals (79; parathyroid levels in such patients with orally administered 1,25-(OH) 2 D 3 was also not dramatic. However, when DeLuca, personal observations). It is possible that the differentiation may be triggered by more than one system an intravenous route was used, excellent treatment of secondary hyperparathyroidism of renal failure resulted providing a redundancy and hence the failure to observe a lesion in skin as a result of vitamin D deficiency. To-(308). These results strongly suggested that 1,25-(OH) 2 D 3 may have a direct action through its receptor in the para-gether with the differentiation of the keratinocyte comes an inhibition of proliferation. This inhibition of proliferathyroid glands. Thus PTH secretion by isolated parathyroid glands or cells could be suppressed by the direct tion has been utilized in the treatment of hyperproliferative diseases of skin as, for example, psoriasis (144, 309 (303) have shown un-entiation of the keratinocyte. During the differentiation process, there is an increase in the protein involukrin equivocally the presence of a VDRE in the promoter region of the parathyroid gene. Although this was first (326). There is an increase in transglutamanase activity (326) and cornified envelope formation (263) . However, thought to be a single 6-base response element, subsequent work has revealed that in actual fact it represents exactly how 1,25-(OH) 2 D 3 induces differentiation of the keratinocyte and inhibits proliferation is unknown and a DR-3 in which two repeat sequences are indeed found at 123-108 bases 5 from the transcriptional start site (76) . remains to be investigated.
Finally, it has been proposed that the keratinocyte This responsive element system causes a suppression of expression of the preproparathyroid gene promoter. De-functions in a paracrine fashion in which 1,25-(OH) 2 D 3 is produced by the keratinocyte itself, and this compound tails of the mechanism are discussed in section III. In addition to the role of the vitamin D hormone in serves as a paracrine to stimulate differentiation of the keratinocyte (21). If this is true, it remains to be exsuppressing the parathyroid gene is the idea that the vitamin D hormone also suppresses proliferation of the parathyroid plained how vitamin D-deficient animals are able to obtain mature and functional keratinocytes. There have gland cells. The discovery by Suda and co-workers (1, 334) that 1,25-(OH) 2 D 3 can suppress the growth and stimulate been very dramatic statements made that the keratinocyte is fully able to metabolize 25-OH-D 3 to 1,25-(OH) 2 D 3 cellular differentiation of the promyelocytes brought forth the idea that 1,25-(OH) 2 D 3 might also suppress proliferation but that it lacks the ability to 25-hydroxylate 1a-OH-D 3 (21). In work carried out in the rat by two different of the parathyroid gland cells. This rationale provides further impetus to the idea that renal osteodystrophy patients laboratories (277, 299), there was a failure to detect any 3 H-labeled 1,25-(OH) 2 D 3 in skin or other tissues in neshould be treated with 1,25-(OH) 2 D 3 to prevent the development of hypertrophied parathyroid glands as well as to sup-phrectomized rats given the highest specific activity (160 Ci/mmol) of 3 H-labeled 25-OH-D 3 available. Thus, in norpress secretion of the PTH. mal rats, the keratinocyte was unable to produce significant amounts of 1,25-(OH) 2 
D. Role of 1a,25-Dihydroxyvitamin D 3 in the Immune System
The presence of the VDR in activated T lymphocytes was reported by Provvedini et al. (267) , who also showed that resting lymphocytes do not express the VDR. Certainly the thymus, which is a repository of immature lymphocytes, is a source of VDR, since it was used as a source of receptor for measurements of 1,25-(OH) 2 D 3 (138) . Among the antigen-presenting cells, the macrophage that is derived from the monocyte has receptors for 1,25-(OH) 2 D 3 (20, 264) . There is no doubt, therefore, that the immune system does indeed possess receptors to 1,25-(OH) 2 D 3 . These results suggest a role for 1,25-(OH) 2 D 3 in the immune system. However, the role is just now beginning to be defined. There have been many reports using peripheral blood lymphocytes that suggest that produc- In a study of delayed hypersensitivity, which is a T-expected to be sufficient (116) . More recently, EAE in B10.PL mice could be completely prevented by the addition of 1,25-helper cell lymphocyte-mediated response, vitamin D deficiency markedly reduces the ability of the mouse to re-(OH) 2 D 3 to the diet of such mice. Furthermore, if the hormonal substance was begun after the EAE had begun, the spond (364). However, large amounts of 1,25-(OH) 2 D 3 and its analogs will also suppress the delayed hypersensitivity development of symptoms could be prevented (Fig. 9) (49) .
Current results strongly suggest that the vitamin D hormone response (363) . These results illustrate that the T-helper cell lymphocyte system is vitamin D responsive but that and its analogs are functioning by stimulating Th-2 T-helper cells to produce transforming growth factor-b1 and IL-4 that both immunostimulation and immunosuppression can be found in the in vivo situation. Currently, there is little might serve to suppress the TNF-a and interferon-g production by Th-1 cells (51). Similar results were obtained with or no evidence to support the idea that B cell-mediated immunity is affected by 1,25-(OH) 2 D 3 .
another autoimmune disease, rheumatoid arthritis induced by Borrelia burgdorferi or Lyme's disease (50) or arthritis The most dramatic results obtained to date in the immune system are those found in several autoimmune dis-produced by the injection of collagen into susceptible mice (50) . Some improvement has also been reported for the autoeases. Most notably is the autoimmune disease known as experimental autoimmune encephalomyelitis (EAE) that can immune induction of diabetes in the nonobese diabetic mouse (218) . The idea, therefore, that the vitamin D combe induced in B10.PL mice or SJL mice by the injection of myelin basic protein together with small amounts of pertus-pounds may play a role in modulating the immune system is strongly supported. Furthermore, there is the idea that sis toxin (49). This treatment induces a multiple sclerosislike disease (EAE). This disease is aggravated by agents that 1,25-(OH) 2 D 3 and its analogs might become useful in the prevention or treatment of autoimmune diseases. stimulate T-helper (Th)-1 cells and that increase interferong and TNF-a secretion (280). Injections once every other Of some interest is the idea that the immunomodulatory action of vitamin D might be useful in the manageday of 1,25-(OH) 2 D 3 in some cases produced a reduction in the severity and in other cases produced very slight re-ment of transplant rejection. Initial work indicates that the vitamin D hormone and its analogs would only be sponses (36, 196) . However, since 1,25-(OH) 2 D 3 has a lifetime marginally useful in prevention of transplant rejection and F. Role of Vitamin D and Reproduction might only be considered as an adjunct to the well-established cyclosporin method of preventing transplant rejecBecause of the focus of scientists on the role of vitation (195) . However, more recently, the administration of min D in calcium homeostasis and regulation of phos-1,25-(OH) 2 D 3 and its analogs in the diet and thus their phate metabolism, the possibility that vitamin D might be provision in a continuous manner has shown that it can involved in reproduction has been largely ignored in the be much more effective than cyclosporin itself in preven-past. However, during the course of producing vitamin Dtion of transplant rejection (D. A. Hullett, M. T. Cantorna, deficient embryos came the observation that female repro-C. Redaelli, J. Humpal-Winter, H. W. Sollinger, and H. F. duction is markedly and significantly diminished in vitaDeLuca, unpublished data). It has been used effectively min D deficiency (122) . Thus a reduction in fertility of to prolong transplant survival beyond that achieved by 80% was found and could not be corrected by correcting cyclosporin in mouse embryonic cardiac transplants and the hypocalcemia (191) . This defect, therefore, is quite in a vascularized cardiac transplant model in the rat. Of clearly one related to an absence of the vitamin D molegreat interest is that the prevention of transplant rejection cule. Similar female reproductive failure was noted in the by the vitamin D compounds was not accompanied by a transgenic receptor knockout mice described by Yoshibone loss phenomenon as is the case with cyclosporin A zawa et al. (365 (324, 325) . and H. F. DeLuca, unpublished data). However, the exact Other organs involved in female reproduction, i.e., the role of how the vitamin D hormone affects T-lymphocyte hypothalamus, also contain VDR. It has been suggested cell populations, cytokine secretion, and production is not that the ovary therefore is a target of vitamin D action. entirely known. There has been a suppressive element In experiments carried out in the authors' laboratory, the reported for the IL-2 gene for the VDR. Whether this is a VDR levels of the ovary are increased during estrus and significant mechanism or not remains to be determined.
diminished during proestrus (348) . These results suggest that female rats may not ovulate properly. The infertility brought about by vitamin D deficiency in the female rat can be easily corrected by the administration of 1,25-E. Islet Cells of the Pancreas (OH) 2 D 3 (191) . These results suggest a role for the vitamin D hormone and its receptor in ovarian function; however, The intriguing finding of a nuclear localization of 1,25-the mechanism remains to be found. (OH) 2 D 3 in the islet cells of the pancreas has led to a
In the case of male reproduction, vitamin D deficiency speculation that vitamin D might be involved in glucose also reduces the effectiveness of the male (190) . However, regulation of insulin secretion (324, 325) . The presence of this diminished male fertility can be corrected by merely a VDR in these cells by now is well accepted, but it is providing additional calcium, raising plasma calcium conunclear as to what, if any, role vitamin D plays in the centration which in turn restores fertility (190) . Thus there functioning of the islet cells. Initial results reveal that does not appear to be a role for the vitamin D hormone in vitamin D-deficient rats were unable to respond to a glu-spermatogenesis and male reproduction. cose challenge by secreting appropriate amounts of insulin (65). Although this could be corrected by the adminis-G. Does Vitamin D Play an Essential Role During tration of 1,25-(OH) 2 D 3 , other studies suggested that this Embryonic Development? was mediated by the action of vitamin D in raising plasma calcium concentration (66) . The problem, therefore, is that it is unclear whether the regulation of insulin secreThis question intrigued investigators in this field a couple of decades ago. The interest in this possibility was tion may have a vitamin D component because of the direct actions of calcium concentration on the functioning intensified when Suda and colleagues (1, 334) demonstrated for the first time the role of 1,25-(OH) 2 D 3 in promyof the islet cells. Nevertheless, the idea that inappropriate responses of the islet cells to a glucose challenge suggests elocyte differentiation. This was followed by work which illustrated that cancer cell lines also responded by differthat a role of the vitamin D hormone is involved. These findings must also be coupled to the experiments carried entiating in response to 1,25-(OH) 2 D 3 (91) . This then provided the basis for believing that the vitamin D hormone out in the nonobese diabetic mouse in which the onset of diabetes is delayed or retarded by the administration of is also a developmental hormone. However, vitamin Ddeficient rats are able to reproduce albeit at only 20% of 1,25-(OH) 2 D 3 (218) . The relationship between vitamin D and diabetes is certainly worthy of additional investiga-normal, but the embryos develop approximately normally to parturition (121) . Furthermore, the provision of suffition.
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09-23-98 14:33:23 pra APS-Phys Rev cient nutrients to the pups allows them to develop approx-able calcemic agents capable of the correction of hypocalcemia and bone abnormalities (rickets and osteomalacia) imately normally until weaning (37) . It is at this time that the dependency on vitamin D becomes very obvious. resulting from a variety of causes from simple vitamin D deficiency to chronic renal failure. There were early These results strongly suggest that vitamin D does not play an essential role in differentiation and development indications that patients with osteoporosis might benefit from the use of an active vitamin D preparation. As a during embryogenesis. It does not exclude, however, that the vitamin D hormone plays an important role in terminal result, it is not surprising that clinical trials of 1a-OH-D 3 (129, 254), 1a-OH-D 2 (106), and 1,25-(OH) 2 D 3 (7, 9, 108, differentiation of specific cell types, as for example the differentiation and formation of osteoclasts. It does argue, 257, 343, 351) have been undertaken. Modest gains in bone mineral density and reductions in fracture rates were rehowever, that 1,25-(OH) 2 D 3 is not involved in the development of major organ systems. These results are supported ported in many of these studies, and this subject has been reviewed recently by Cali and Russell (44) and Seeman very strongly by the receptor knockout mice and by the vitamin D-dependency rickets type II cases which are the et al. (293) . Consequently, 1,25-(OH) 2 D 3 and 1a-OH-D 3 are currently used to treat osteoporosis, particularly in Japan human example of receptor knockouts. In these cases, the fetuses develop normally and, in fact, appropriately and Europe, where dietary calcium intakes are often lower and hypercalcemic side effects not so prevalent. fed, the animals will survive to day 55 (365) . If in the absence of receptor the major organ systems develop norAlthough vitamin D analogs continued to be synthesized in the late 1970s, the emergence of the newer nonmally, it provides little support for the idea that vitamin D is an important developmental vitamin. One might argue classical functions of 1,25-(OH) 2 D 3 , particularly the discovery of its role in controlling cell proliferation and difthat there are nongenomic actions of 1,25-(OH) 2 D 3 ; however, there is insufficient evidence for this concept at this ferentiation (228, 252) (see sect. IV), led to an acceleration in the pace of the search for new analogs. The chemical time as well (195) . Therefore, it is the view of these authors that 1,25-(OH) 2 D 3 is not a major developmental hor-synthesis of new analogs of 1,25-(OH) 2 D 3 became a major priority with the hope that the calcemic properties of 1,25-mone at least involved in the development of major organ systems during embryogenesis.
(OH) 2 D 3 might be separated from the antiproliferative cell-differentiating properties (119, 157) . Hundreds of molecules have now been synthesized in pursuit of this goal, H. Summary and a couple of recent reviews have attempted to classify or list all published vitamin D analogs in a detailed fashion Scientists are just beginning to investigate the new (20, 31, 47, 104). For the sake of brevity, we have selected and previously unappreciated functions of the vitamin D some of the more promising of these that are under develhormone. They include functions in the parathyroid opment by the pharmaceutical industry in Table 1 . Those glands, the keratinocytes of skin, the T cells and macro-selected are not the only analogs being developed, but all phages of the immune system, the islet cells of the pan-are at some advanced stage of animal or clinical testing. creas, and ovarian cells of the female. There is the possi-From perusal of the compounds in Table 1 , the reader bility that additional functions will be found in such sys-will immediately notice that the side chain appears to be tems as the islet cells of the pancreas, mammary cell a popular target for modification, and there is a rational epithelium, and cells in the hair follicle system. basis for this, namely, that the VDR is relatively tolerant of changes in this part of the molecule. However, since 1980, the synthetic chemist has experimented with modi-V. VITAMIN D ANALOGS fication of every part of the vitamin D molecule in an attempt to accentuate either the antiproliferative or cal-A. Development of New Analogs cemic properties. The full extent of these synthetic modiof 1a,25-Dihydroxyvitamin D 3 fications is best displayed as the annotated structure illustrated in Figure 10 . Probably the most successful 1,25-(OH) 2 D 3 analog developed thus far is the Leo antipsoriatic The discovery of 1,25-(OH) 2 D 3 and the other metabolites of vitamin D in the early 1970s immediately led to drug calcipotriol, also known as MC903, which was the first vitamin D analog to reach the market for any conditheir chemical synthesis and to the first generation of compounds suitable for hormone replacement therapy tion other than hypocalcemia or bone disease (45). When given orally, calcipotriol is ineffective due to the fact that (13, 294) . In addition to 1,25-(OH) 2 D 3 , most notable among these were the prodrugs 1a-OH-D 3 and 1a-OH-D 2 , which it is rapidly broken down (24, 354). When given topically as an ointment, calcipotriol survives long enough to cause were designed to overcome the need for a functional kidney containing the 1a-hydroxylase enzyme, instead, de-improvement in 70% of psoriasis patients (18, 181). Both 1,25-(OH) 2 D 3 and calcipotriol are believed to be effective pending only on the need for 25-hydroxylation (193, 258) . Although little is modifications at C-22 and C-23 which affect the metabolic stability of the molecules without adversely altering the known at this time about the biological success of this experiment, it is certain to lead to other more exotic dou-VDR binding. 22-Oxacalcitriol is in development for use in secondary hyperparathyroidism, while EB1089 is in ble-side chain molecules with symmetrical and asymmetrical structures around C-20 (Fig. 11) . In the asymmetrical clinical trial for treatment of breast cancer. Another successful modification has been the addition of carbons to double-side chain analog (Fig. 11) featuring one 23-oxa side chain and one normal side chain, X-ray structural the backbone or terminus of the side chain (termed homologation), examples being EB1089 and KH1060 (124) . analysis (188) has revealed the orientation of the two side chains and a measure of the range of conformational The latter analog epitomizes the latest generation of vitamin D analogs, in that it contains a combination of modi-structures that can be accommodated by the ligand binding pocket of the VDR, since it is known to bind both 20S-fications; in the case of KH1060, four modifications: an extra C at C-24a; additional terminal carbons at C-26a and and 20R-analogs. Equally interesting and perhaps more practical from which appears to extend its lifetime in vivo. An extensive collaboration between the De Clerq and Bouillon laboraa biological activity perspective are analogs with modifications of the cis-triene, either changing the conforma-tories has generated many new analogs with modification in the C and D rings, although at present many of these tion of the double bonds to create molecules with an altered cis-triene (250) or analogs that lack the C-10 to are only partially tested biologically (29, 78) . One interesting spin-off from the latter research is the synthesis of C-19 methylene group altogether such as 19-nor-1,25-(OH) 2 (29) . It will be interesting to see has lost the double bond between C-10 and C-19 but retains the C-19 as a methyl group not a methylene, as why E-ring analogs show good in vitro activity but appear to be devoid of in vivo activity. is the case in almost all other vitamin D compounds. Dihydrotachysterol is metabolized to 25-hydroxylated and 1,25-dihydroxylated forms, both of which bind to B. Factors That Alter the Action VDR and are biologically active, explaining why DHT of Vitamin D Analogs was once the analog of choice for hypocalcemia, particularly that associated with chronic renal failure (158, 268) .
From the synthesis of literally hundreds of analogs has The experiments with 19-nor-1,25-(OH) 2 D 2 and DHT emerged a clearer understanding of the factors that are imshow that the 10 -19 double bond and the C-19 carbon portant in changing the action of the specific analog relative are probably superfluous for vitamin D-dependent gene to 1,25-(OH) 2 D 3 . These are listed in the following sections. expression. As with several other analogs, 19-nor-1,25-(OH) 2 D 2 appears effective in the treatment of hyperpara-1. Activating enzymes thyroidism associated with chronic renal failure (307) .
Further excursions into A-ring or C-and D-ring modiThe natural hormone of vitamin D is activated by sequential steps in the liver and kidney as described in fications are currently underway. One molecule into clinical trial for the treatment of osteoporosis is the Chugai section I. The distribution and pharmacokinetics of 1,25-(OH) 2 D 3 depend on these steps occurring efficiently at analog ED-71, which is modified at C-2 of the A ring by the addition of a hydroxypropoxy group (241), a feature substrate concentrations that circulate bound to DBP and/ or are available in the respective tissues. The strategy for DBP is inversely correlated with its rate of clearance from the bloodstream. Those metabolites with the strongwith most synthetic analogs is to synthesize a molecule with both 25-and 1a-hydroxyl groups and miss out the est affinity for DBP [e.g., 25-OH-D 3 , 24,25-(OH) 2 D 3 , and 25-OH-D 3 -26,23-lactone] possess the longest half-life valneed for these activation steps. The disadvantage of this approach is that the body loses its ability to regulate the ues in the blood on the order of days (17, 26) . Those metabolites such as 1,25-(OH) 2 D 3 have lower affinity and amount of the active principle in the blood and target cell, with the success of the therapy being heavily dependent half-life values on the order of hours. These basic concepts were confirmed by our experience with analogs of on the pharmacokinetics of the specific analog.
On the other hand, the use of prodrugs such as 1a-1,25-(OH) 2 D 3 . Clearly, some modifications are detrimental to DBP OH-D 3 circumvents some of these problems by introducing a step of activation back into the process, albeit by a binding such as the addition of a 1a-hydroxyl group. Other modifications such as the addition of the double bond different regulatory enzyme. This activating enzyme is in essence a ''slow-release'' mechanism for delivering the between C-22 and C-23 or the addition of a C-24 methyl group, as in the metabolites of vitamin D 2 , do little to same ''active form,'' 1,25-(OH) 2 D 3 , with altered pharmacokinetics. This is because the activating enzyme has been affect binding to mammalian DBP but dramatically lower the binding of these compounds to avian DBP (17). changed from the tightly regulated renal 1a-hydroxylase to the loosely regulated liver 25-hydroxylase. Although However, the findings with D 2 compounds with mammalian DBP go against the general rule, and most 1a-hydroxthis was believed to be a simple strategy to get around dependence on the easily damaged renal enzyme when it ylated, side chain-modified analogs have inferior DBP binding compared with 1,25-(OH) 2 D 3 . Calcipotriol, OCT, was conceived in the 1970s, the emergence of CYP27 as one of the enzymes responsible for the 25-hydroxylation EB1089, KH1060, and 20-epi-1,25-(OH) 2 claimed that OCT derives part of its usefulness for treatment of hyperparathyroidism from its accumulation in Another aspect of the activation strategy that was overlooked at first glance was the potential of producing parathyroid tissue in vivo, possibly caused by an altered plasma transport on lipoprotein (176) . multiple active forms from the same administered prodrug. The analog 1a-OH-D 2 has consistently proven to be Second, the rate of metabolic clearance is affected by altering DBP affinity. Consistent with the findings for less toxic than its D 3 counterpart in animal studies and clinical trials (93, 306) . The explanation for these findings vitamin D metabolites, a reduction in DBP binding for a given vitamin D analog leads to even more rapid excretion remains obscure but may be due to the fact that 1a-OH-D 2 gives rise to two biologically active products, 1,25-than that observed for 1,25-(OH) 2 D 3 . Calcipotriol binds DBP with an affinity two to three orders of magnitude (OH) 2 D 2 and 1,24-(OH) 2 D 2 (320), each with its own set of slightly different pharmacokinetic parameters compared lower than 1,25-(OH) 2 D 3 (171). When given systemically, calcipotriol is metabolized and excreted so rapidly that it with 1,25-(OH) 2 D 3 (175) . CYP27 is capable of the efficient synthesis of 1,24-(OH) 2 D 2 (119). The enzyme responsible has no biological effects even at 50 times the dose used for the natural hormone. As described above, it is only for the synthesis of 1,25-(OH) 2 D 2 remains unknown. Whether this strategy of delivering a prodrug which be-effective because it is topically administered in an ointment and is rapidly cleared (and metabolized) before it cause of its structure is activated by different enzymes with altered distribution or gives rise to more than one can reach tissues involved in calcium homeostasis. Thus DBP binding is an important parameter in dictating in active metabolite offers therapeutic advantages remains moot at this time.
vivo biological activity. Third, the affinity of the analog for DBP influences 2. Binding to DBP the rate of cell uptake. Given that it is the ''free'' fraction of the plasma-borne ligand which is believed to gain acIt has been recognized since the discovery of the various vitamin D metabolites that the affinity of an analog cess to the target cell and function by binding to the recep-tor (VDR) in the classical steroid hormone model (see consistently only one or two orders of magnitude more potent than 1,25-(OH) 2 D 3 in gene transactivation assays, sect. III), it is therefore no surprise that this might also be the case for vitamin D analogs. Many analogs have the a difference that could be explained by using the transcriptional model of analog action in conjunction with same affinity for VDR as 1,25-(OH) 2 D 3 , which when combined with a lower affinity for DBP than 1,25-(OH) 2 On the other hand, when this effect of DBP, greater genes (e.g., those associated with immunoregulatory or cell regulatory responses), currently the data do not support access to target cells, is considered along side its other effect, more rapid clearance at the liver, in the animal in this (128, 322). It should be noted that in a recent review (53) it was theorized that 1,25-(OH) 2 D 3 (and thus vitamin vivo, the net effect is usually not so advantageous. This is presumably because these two effects are counteractive D analogs) might be able to act through as many as 14 different heterodimeric response element combinations to and the vitamin D analog cannot be active unless it reaches the target cell in sufficient concentrations to gain modulate gene expression, but the physiological relevance of the majority of these has yet to be established. greater access and produce its target cell biological effects. In the case of analogs such as ED-71, chemists have
To add to the complexity of the target cell action of 1,25-(OH) 2 D 3 , and thus that of vitamin D analogs, is the created a longer lasting analog that may give reduced biological activity but for a longer period of time. In es-type and context of the VDRE involved (40) . The work of Williams and co-workers (40, 166, 360) shows that comsence, they have altered the pharmacokinetics again.
pared with 1,25-(OH) 2 D 3 , KH1060 and EB1089 show different patterns of gene activation in bone marrow, osteoblas-
Binding to VDR-RXR-VDRE complexes
tic cells (ROS17/2, ROS25/1, and UMR106), and intestine (HT-29 and Caco-2) which appear to be gene and cell Section III of this review has established that 1,25-(OH) 2 D 3 is able to work through a VDR-mediated genomic specific. These data are probably explained by the changes in available transcription factors acting at VDRE mechanism to stimulate transcriptional activity at vitamin D-dependent genes. Whether 1,25-(OH) 2 D 3 works through in different tissues and at different stages of cell differentiation (317). Furthermore, there have been reports of a other nongenomic mechanisms to produce physiologically relevant effects is a theory that, in our opinion, re-nonclassical VDRE in the promoter of the c-fos gene (48) that could theoretically respond differently to ''noncalmains unproven (244).
Much evidence exists to support the viewpoint that cemic'' and ''calcemic'' analogs, but this has not been demonstrated experimentally. Furthermore, Morrison and Eisvitamin D analogs operate by mimicking 1,25-(OH) 2 D 3 and using a genomic mechanism. The first clue that vitamin D man (229) showed that a noncalcemic analog such as calcipotriol is capable of transactivating a calcemic VDRE analogs can work through a VDR-mediated transcriptional mechanism came 15 years ago from the bone resorption such as the human osteocalcin promoter VDRE placed in front of the chloramphenicol acetyltransferase reporter studies reported by Stern (318). Stern (318) showed that there exists a strong correlation between chick intestinal gene and stably transfected into ROS17/2 cells. One interpretation of this experiment is that a noncalcemic analog VDR binding of an analog and its potency in a 45 Ca rat bone resorption assay. This suggests that a vitamin D ana-with good VDR affinity is just as calcemic as 1,25-(OH) 2 D 3 if it can be delivered to the target cell. log is only as good as its affinity for the VDR. Certainly, there are some apparent exceptions to this general rule, A more recent hypothesis put forward to explain the unique properties of certain vitamin D analogs is that they but these are not discrepancies that cannot be explained by considerations such as DBP binding or pharmacokinet-generate different conformations of the ligand-VDR-RXR heterodimer which result in altered binding at the VDRE. ics. Preliminary results with the analogs KH1060, EB1089, and 20-epi-1,25-(OH) 2 (259, 352) . The increased resistance to trypsin digestion provided to out multiple steps in the C-24 oxidation process, is vitamin D inducible, and is present in many (if not all) vitamin D VDR by KH1060 binding is mimicked by the most active metabolites of KH1060, suggesting that certain receptor con-target cells. We have postulated that the purpose of this catabolic pathway is to desensitize the target cell to conformations might correlate with increased biological activity (353) . The use of truncated VDR mutants has allowed the tinuing hormonal stimulation by 1,25-(OH) 2 D 3 (203) . One can also ask the question: Are vitamin D analogs subject work on KH1060 to be extended and to potentially reveal the amino acid residues involved in these conformational to the same catabolic metabolism? And, if not, are other drug-catabolizing systems present within vitamin D target differences and in ligand binding (200) . In the future, it is to be expected that the generation of large quantities of cells to inactivate the vitamin D analog?
We now have a good idea as to the answer to these the ligand-binding domain of the VDR using bacterial or baculovirus-generated material (323) will permit the deter-questions, but the answers are analog specific. Certainly, there are metabolism-sensitive analogs such as calcipomination of the three-dimensional structure with and without ligand [1,25-(OH) 2 D 3 or vitamin D analog] by NMR or X-triol and OCT that are metabolized very rapidly by target cell enzymes to clearly defined and unique metabolites ray crystallographic analysis. For now, we can draw on the experience gained from related fields. If the findings from (213, 215) that resemble products of the 24-oxidation pathway for 1,25-(OH) 2 D 3 . The provision of such features as X-ray crystallographic studies of various retinoid receptors (apo-RXR and holo-RAR ) are relevant to VDR, then the a 22-oxa group seems to accelerate the rate of metabolism of OCT, and the 24-hydroxyl group of calcipotriol is a site orientation of the COOH terminus containing the AF-2 domain will turn out to be dramatically altered upon vitamin for deactivation. The rapid metabolism of calcipotriol by cultured keratinocytes in vitro (215) correlates well with D analog binding and to be very important to the interaction with the other proteins of the transcription initiation com-the in vivo findings that it is rapidly broken down when administered topically and fails to reach tissues involved plex (279). Moras and co-workers (361) have already used computer modeling based on his RAR model to predict the in calcium homeostasis (24). One does not need to invoke hepatic metabolism as the principal site of inactivation, orientation of ligands including vitamin D analogs in the binding pocket of the VDR. He predicts that 1,25-(OH) 2 D 3 even though this tissue can also break down calcipotriol (24, 215). and various analogs bind with side chain deep into the ligand-binding pocket and A ring close to the putative ''trapAnalogs that appear to be slowly metabolized by target cells include EB1089 and 1,24S-(OH) 2 D 2 (156, 170, door'' (AF-2 domain). Therefore, the observed differences in protease resistance induced by potent 20-epi compounds 295). Both are considered more calcemic than either calcipotriol or OCT but not excessively so. These data are such as KH1060 (259, 352) could be important clues that the AF-2 domain of the heterodimer-analog complex is in a consistent with metabolism-resistant analogs having a longer half-life inside the target cell as compared with slightly different conformation to that of the heterodimer-1,25-(OH) 2 D 3 complex. As a result, these complexes may 1,25-(OH) 2 D 3 and a longer half-life in pharmacokinetic studies (30, 175) , and possibly a higher biological activity recruit additional transcription factors (see sect. III) that may result in qualitative or quantitative differences in gene in vivo, although this is tempered by inferior DBP binding and more rapid clearance from the bloodstream. Interestexpression.
There is some evidence from surface plasmon reso-ingly, both EB1089 and 1,24S-(OH) 2 D 2 are blocked at the C-24 position and cannot enter the C-24 oxidation pathnance studies that a series of Roche analogs causes differences in the association and dissociation rates of VDR-way, leaving C-26 as the new site of hydroxylation, albeit at a slower rate (156, 170, 295) . Another potent analog RXR heterodimers to artificial VDRE-containing oligonucleotide anchored to gold-coated chips (67) . Whether this blocked in the C-24 position is 1,25-(OH) 2 -16-ene-23-yne-D 3 , which is also subject to 26-hydroxylation (288). Studtranslates into increased stability of specific complexes on the vitamin D-dependent gene promoter in vivo remains to ies with EB1089 using transfected human CYP27 suggest that this cytochrome is not responsible for the 26-hydroxbe proven. In summary, researchers continue to probe the many steps of the gene transcription activation process ylation observed (295). However, Suda and co-workers (227) have concluded that the other candidate cytoin the hope of finding a fundamental difference between 1,25-(OH) 2 D 3 and its analogs that may explain their im-chrome P-450, CYP24 may be responsible for 26-hydroxylation of the 24-blocked analog 24,24-F 2 -1,25-(OH) 2 D 3 inproved potency or their action at only selected genes. Thus far, they have more questions than answers.
side kidney cells. Another metabolic complication brought on by the 4. Target cell and liver catabolic enzymes use of vitamin D analogs is the potential for creating ''active'' rather than ''inactive'' products as a result of As stated in section I, much evidence has accumulated to support the hypothesis that 1,25-(OH) 2 D 3 is sub-target cell enzymes. Three examples of this have now been documented, and this may be more common than more general catabolic enzymes found in the liver. One interesting example is the enzyme that saturates the douwe think. The potent calcemic analog 26,27-F 6 -1,25-(OH) 2 D 3 is converted both in vivo and in vitro, presum-ble bond between C-22 and C-23 in the side chain of calcipotriol but does nothing to the same bond in the ably by the cytochrome CYP24 into 26,27-F 6 -1,23,25-(OH) 3 2 D 3 in a reporter gene expression group in calcipotriol is enough to allow the saturase enzyme to function. As vitamin D analogs continue to devisystem. Thus a metabolite may explain the long-lasting effects of the parent analog. In a second example, Dil-ate more from the classical structure, they become more and more susceptible to general purpose or unrelated worth et al. (87) recently showed that KH1060 is metabolized very rapidly in vitro and in vivo into as many as 22 enzyme systems.
It should be noted with regard to molecular mechametabolites but that some of these metabolites retain significant biological activity in similar reporter gene nisms of action at the target cell level that metabolism is often disregarded or given too little emphasis. Metabolic assay systems. The most abundant of these metabolites include 26-hydroxy and 24a-hydroxy KH1060, which can assumptions are made when testing biological activity in vitro that are not always valid. These include 1) the analog be detected in the blood in vivo, are stable in vitro, and as stated earlier can form trypsin-resistant complexes is biologically active as administered and 2) the analog has the same stability as 1,25-(OH) 2 D 3 in the in vitro target with VDR (87, 353). At the very least, these active metabolites of KH1060 may explain its high potency when com-cell model used, whether in in vitro organ culture, cultured target cell, or host cell/reporter gene construct. The pared with 1,25-(OH) 2 D 3 using in vitro assays. In addition, the findings may also explain the disappointing per-validity of this approach is made even more tenuous when data acquired with different in vitro models, where metaformance of KH1060 in vivo, since the metabolites are not allowed to accumulate and are rapidly cleared from bolic considerations may or may not apply, are compared with data acquired in vivo, where metabolic considerathe bloodstream. The third example of possible activation of an analog is 3-epimerization (275) . Using in vitro tions do apply. The reader is cautioned that invalid comparisons of in vivo and in vitro data abound in this field. cultured cell and perfused kidney systems where artificial media and high analog concentrations are employed, The outcome is that a number of promising in vitro-tested vitamin D analogs have been found to be inactive when several researchers have observed the 3-epimerization of vitamin D analogs [e.g., 1,25-(OH) 2 D 3 itself] (214, 224, tested in vivo. 275). As with the example of KH1060, the claim is not 5. Relative importance of key factors on vitamin D that the metabolic product 3-epi-1,25-(OH) 2 D 3 is more analog action active than the parent compound, just that it retains sigIt is evident that vitamin D analogs differ from 1,25-nificant biological activity and is more stable, not being (OH) 2 D 3 in a variety of ways: activating enzymes, DBP subject to the C-24 oxidation pathway which is the fate affinity, VDR-RXR-VDRE-gene association, and catabolic that befalls the hormone. The nature of the enzyme inenzyme susceptibility. Any one or a combination of these volved is currently undefined but is reminiscent of the differences could be important in making a specific analog behavior of steroidal 3a-and 3b-oxidoreductases. Moreappear calcemic or noncalcemic or work in vitro but not over, the formation of 1a-and 1b-hydroxylated DHT in in vivo, or vice versa. Although it is attractive at this time rats and humans in vivo, referred to in section VA, resemto consider as most important the subtle VDR conformables the 3-epimerization of vitamin D analogs and sugtional differences induced by analogs as compared with gests that the process may be more than just an in vitro 1,25-(OH) 2 D 3 , there is a wealth of information that argues artifact. Nevertheless, the main hurdle for proponents of that metabolism, transport, and pharmacokinetics play a the 3-epimerization hypothesis is that they must show major role in vivo. the metabolic step can occur in vivo.
With our existing in vitro cell systems, it is difficult The final metabolic consideration is hepatic modifito study any one of these factors to the total exclusion of cation. The liver is believed to be devoid of VDR and the all others. Thus it seems unlikely that we shall be able to inducible cytochrome P-450; CYP24 and cultured liver determine the relative importance of all of the factors cells (Hep G2 and Hep 3B) do not appear to degrade the listed until we have a fully functional cell-free in vitro hormone 1,25-(OH) 2 D 3 very rapidly (213, 215). However, model for transcription so that analogs can be tested withthe story with vitamin D analogs appears to be quite out the complication of metabolic enzymes. different. Analogs such as calcipotriol and OCT are broken down by liver enzymes, these presumably contribut-C. Future Directions in Vitamin D Drug Design ing to the rapid metabolic clearance observed in vivo (213, 215). As the analog structure is modified away from
The growing availability of recombinant cytochromes P-450 will allow for a search for potential inhibitors. Such the vitamin D prototype, it becomes vulnerable to other / 9j0c$$oc10 09-23-98 14:33:23 pra APS-Phys Rev
Cloning, structure and expression of the mitochondrial cytochrome specific inhibitors of CYP24 may be of value in blocking be able to explore the permitted boundaries for optimal 3294-3298, 1988. protein binding. More rational vitamin D analog design
